Search This Blog

Monday, August 22, 2022

Model organism

From Wikipedia, the free encyclopedia
 
Drosophila melanogaster, one of the most famous subjects for genetics experiments
 
Saccharomyces cerevisiae, one of the most intensively studied eukaryotic model organisms in molecular and cell biology

A model organism (often shortened to model) is a non-human species that is extensively studied to understand particular biological phenomena, with the expectation that discoveries made in the model organism will provide insight into the workings of other organisms. Model organisms are widely used to research human disease when human experimentation would be unfeasible or unethical. This strategy is made possible by the common descent of all living organisms, and the conservation of metabolic and developmental pathways and genetic material over the course of evolution.

Studying model organisms can be informative, but care must be taken when generalizing from one organism to another.

In researching human disease, model organisms allow for better understanding the disease process without the added risk of harming an actual human. The species chosen will usually meet a determined taxonomic equivalency to humans, so as to react to disease or its treatment in a way that resembles human physiology as needed. Although biological activity in a model organism does not ensure an effect in humans, many drugs, treatments and cures for human diseases are developed in part with the guidance of animal models.

There are three main types of disease models: homologous, isomorphic and predictive. Homologous animals have the same causes, symptoms and treatment options as would humans who have the same disease. Isomorphic animals share the same symptoms and treatments. Predictive models are similar to a particular human disease in only a couple of aspects, but are useful in isolating and making predictions about mechanisms of a set of disease features.

There are many model organisms. One of the first model systems for molecular biology was the bacterium Escherichia coli, a common constituent of the human digestive system. Several of the bacterial viruses (bacteriophage) that infect E. coli also have been very useful for the study of gene structure and gene regulation (e.g. phages Lambda and T4). However, it is debated whether bacteriophages should be classified as organisms, because they lack metabolism and depend on functions of the host cells for propagation.

Model organisms are drawn from all three domains of life, as well as viruses. Examples include Escherichia coli (E. coli), baker's yeast (Saccharomyces cerevisiae), the T4 phage virus, the fruit fly Drosophila melanogaster, the flowering plant Arabidopsis thaliana, guinea pigs (Cavia porcellus), and the mouse (Mus musculus).

History

The use of animals in research dates back to ancient Greece, with Aristotle (384–322 BCE) and Erasistratus (304–258 BCE) among the first to perform experiments on living animals. Discoveries in the 18th and 19th centuries included Antoine Lavoisier's use of a guinea pig in a calorimeter to prove that respiration was a form of combustion, and Louis Pasteur's demonstration of the germ theory of disease in the 1880s using anthrax in sheep.

Research using animal models has been central to many of the achievements of modern medicine. It has contributed most of the basic knowledge in fields such as human physiology and biochemistry, and has played significant roles in fields such as neuroscience and infectious disease. For example, the results have included the near-eradication of polio and the development of organ transplantation, and have benefited both humans and animals. From 1910 to 1927, Thomas Hunt Morgan's work with the fruit fly Drosophila melanogaster identified chromosomes as the vector of inheritance for genes. Drosophila became one of the first, and for some time the most widely used, model organisms, and Eric Kandel wrote that Morgan's discoveries "helped transform biology into an experimental science." D. melanogaster remains one of the most widely used eukaryotic model organisms. During the same time period, studies on mouse genetics in the laboratory of William Ernest Castle in collaboration with Abbie Lathrop led to generation of the DBA ("dilute, brown and non-agouti") inbred mouse strain and the systematic generation of other inbred strains. The mouse has since been used extensively as a model organism and is associated with many important biological discoveries of the 20th and 21st centuries.

In the late 19th century, Emil von Behring isolated the diphtheria toxin and demonstrated its effects in guinea pigs. He went on to develop an antitoxin against diphtheria in animals and then in humans, which resulted in the modern methods of immunization and largely ended diphtheria as a threatening disease. The diphtheria antitoxin is famously commemorated in the Iditarod race, which is modeled after the delivery of antitoxin in the 1925 serum run to Nome. The success of animal studies in producing the diphtheria antitoxin has also been attributed as a cause for the decline of the early 20th-century opposition to animal research in the United States.

Subsequent research in model organisms led to further medical advances, such as Frederick Banting's research in dogs, which determined that the isolates of pancreatic secretion could be used to treat dogs with diabetes. This led to the 1922 discovery of insulin (with John Macleod) and its use in treating diabetes, which had previously meant death. John Cade's research in guinea pigs discovered the anticonvulsant properties of lithium salts, which revolutionized the treatment of bipolar disorder, replacing the previous treatments of lobotomy or electroconvulsive therapy. Modern general anaesthetics, such as halothane and related compounds, were also developed through studies on model organisms, and are necessary for modern, complex surgical operations.

In the 1940s, Jonas Salk used rhesus monkey studies to isolate the most virulent forms of the polio virus, which led to his creation of a polio vaccine. The vaccine, which was made publicly available in 1955, reduced the incidence of polio 15-fold in the United States over the following five years. Albert Sabin improved the vaccine by passing the polio virus through animal hosts, including monkeys; the Sabin vaccine was produced for mass consumption in 1963, and had virtually eradicated polio in the United States by 1965. It has been estimated that developing and producing the vaccines required the use of 100,000 rhesus monkeys, with 65 doses of vaccine produced from each monkey. Sabin wrote in 1992, "Without the use of animals and human beings, it would have been impossible to acquire the important knowledge needed to prevent much suffering and premature death not only among humans, but also among animals."

Other 20th-century medical advances and treatments that relied on research performed in animals include organ transplant techniques, the heart-lung machine, antibiotics, and the whooping cough vaccine. Treatments for animal diseases have also been developed, including for rabies, anthrax, glanders, feline immunodeficiency virus (FIV), tuberculosis, Texas cattle fever, classical swine fever (hog cholera), heartworm, and other parasitic infections. Animal experimentation continues to be required for biomedical research, and is used with the aim of solving medical problems such as Alzheimer's disease, AIDS, multiple sclerosis, spinal cord injury, many headaches, and other conditions in which there is no useful in vitro model system available.

Selection

Models are those organisms with a wealth of biological data that make them attractive to study as examples for other species and/or natural phenomena that are more difficult to study directly. Continual research on these organisms focuses on a wide variety of experimental techniques and goals from many different levels of biology—from ecology, behavior and biomechanics, down to the tiny functional scale of individual tissues, organelles and proteins. Inquiries about the DNA of organisms are classed as genetic models (with short generation times, such as the fruitfly and nematode worm), experimental models, and genomic parsimony models, investigating pivotal position in the evolutionary tree. Historically, model organisms include a handful of species with extensive genomic research data, such as the NIH model organisms.

Often, model organisms are chosen on the basis that they are amenable to experimental manipulation. This usually will include characteristics such as short life-cycle, techniques for genetic manipulation (inbred strains, stem cell lines, and methods of transformation) and non-specialist living requirements. Sometimes, the genome arrangement facilitates the sequencing of the model organism's genome, for example, by being very compact or having a low proportion of junk DNA (e.g. yeast, arabidopsis, or pufferfish).

When researchers look for an organism to use in their studies, they look for several traits. Among these are size, generation time, accessibility, manipulation, genetics, conservation of mechanisms, and potential economic benefit. As comparative molecular biology has become more common, some researchers have sought model organisms from a wider assortment of lineages on the tree of life.

Phylogeny and genetic relatedness

The primary reason for the use of model organisms in research is the evolutionary principle that all organisms share some degree of relatedness and genetic similarity due to common ancestry. The study of taxonomic human relatives, then, can provide a great deal of information about mechanism and disease within the human body that can be useful in medicine.

Various phylogenetic trees for vertebrates have been constructed using comparative proteomics, genetics, genomics as well as the geochemical and fossil record. These estimations tell us that humans and chimpanzees last shared a common ancestor about 6 million years ago (mya). As our closest relatives, chimpanzees have a lot of potential to tell us about mechanisms of disease (and what genes may be responsible for human intelligence). However, chimpanzees are rarely used in research and are protected from highly invasive procedures. Rodents are the most common animal models. Phylogenetic trees estimate that humans and rodents last shared a common ancestor ~80-100mya. Despite this distant split, humans and rodents have far more similarities than they do differences. This is due to the relative stability of large portions of the genome, making the use of vertebrate animals particularly productive.

Genomic data is used to make close comparisons between species and determine relatedness. As humans, we share about 99% of our genome with chimpanzees (98.7% with bonobos) and over 90% with the mouse. With so much of the genome conserved across species, it is relatively impressive that the differences between humans and mice can be accounted for in approximately six thousand genes (of ~30,000 total). Scientists have been able to take advantage of these similarities in generating experimental and predictive models of human disease.

Use

There are many model organisms. One of the first model systems for molecular biology was the bacterium Escherichia coli, a common constituent of the human digestive system. Several of the bacterial viruses (bacteriophage) that infect E. coli also have been very useful for the study of gene structure and gene regulation (e.g. phages Lambda and T4). However, it is debated whether bacteriophages should be classified as organisms, because they lack metabolism and depend on functions of the host cells for propagation.

In eukaryotes, several yeasts, particularly Saccharomyces cerevisiae ("baker's" or "budding" yeast), have been widely used in genetics and cell biology, largely because they are quick and easy to grow. The cell cycle in a simple yeast is very similar to the cell cycle in humans and is regulated by homologous proteins. The fruit fly Drosophila melanogaster is studied, again, because it is easy to grow for an animal, has various visible congenital traits and has a polytene (giant) chromosome in its salivary glands that can be examined under a light microscope. The roundworm Caenorhabditis elegans is studied because it has very defined development patterns involving fixed numbers of cells, and it can be rapidly assayed for abnormalities.

Disease models

Animal models serving in research may have an existing, inbred or induced disease or injury that is similar to a human condition. These test conditions are often termed as animal models of disease. The use of animal models allows researchers to investigate disease states in ways which would be inaccessible in a human patient, performing procedures on the non-human animal that imply a level of harm that would not be considered ethical to inflict on a human.

The best models of disease are similar in etiology (mechanism of cause) and phenotype (signs and symptoms) to the human equivalent. However complex human diseases can often be better understood in a simplified system in which individual parts of the disease process are isolated and examined. For instance, behavioral analogues of anxiety or pain in laboratory animals can be used to screen and test new drugs for the treatment of these conditions in humans. A 2000 study found that animal models concorded (coincided on true positives and false negatives) with human toxicity in 71% of cases, with 63% for nonrodents alone and 43% for rodents alone.

In 1987, Davidson et al. suggested that selection of an animal model for research be based on nine considerations. These include

1) appropriateness as an analog, 2) transferability of information, 3) genetic uniformity of organisms, where applicable, 4) background knowledge of biological properties, 5) cost and availability, 6) generalizability of the results, 7) ease of and adaptability to experimental manipulation, 8) ecological consequences, and 9) ethical implications.

Animal models can be classified as homologous, isomorphic or predictive. Animal models can also be more broadly classified into four categories: 1) experimental, 2) spontaneous, 3) negative, 4) orphan.

Experimental models are most common. These refer to models of disease that resemble human conditions in phenotype or response to treatment but are induced artificially in the laboratory. Some examples include:

Spontaneous models refer to diseases that are analogous to human conditions that occur naturally in the animal being studied. These models are rare, but informative. Negative models essentially refer to control animals, which are useful for validating an experimental result. Orphan models refer to diseases for which there is no human analog and occur exclusively in the species studied.

The increase in knowledge of the genomes of non-human primates and other mammals that are genetically close to humans is allowing the production of genetically engineered animal tissues, organs and even animal species which express human diseases, providing a more robust model of human diseases in an animal model.

Animal models observed in the sciences of psychology and sociology are often termed animal models of behavior. It is difficult to build an animal model that perfectly reproduces the symptoms of depression in patients. Depression, as other mental disorders, consists of endophenotypes that can be reproduced independently and evaluated in animals. An ideal animal model offers an opportunity to understand molecular, genetic and epigenetic factors that may lead to depression. By using animal models, the underlying molecular alterations and the causal relationship between genetic or environmental alterations and depression can be examined, which would afford a better insight into pathology of depression. In addition, animal models of depression are indispensable for identifying novel therapies for depression.

Important model organisms

Model organisms are drawn from all three domains of life, as well as viruses. The most widely studied prokaryotic model organism is Escherichia coli (E. coli), which has been intensively investigated for over 60 years. It is a common, gram-negative gut bacterium which can be grown and cultured easily and inexpensively in a laboratory setting. It is the most widely used organism in molecular genetics, and is an important species in the fields of biotechnology and microbiology, where it has served as the host organism for the majority of work with recombinant DNA.

Simple model eukaryotes include baker's yeast (Saccharomyces cerevisiae) and fission yeast (Schizosaccharomyces pombe), both of which share many characters with higher cells, including those of humans. For instance, many cell division genes that are critical for the development of cancer have been discovered in yeast. Chlamydomonas reinhardtii, a unicellular green alga with well-studied genetics, is used to study photosynthesis and motility. C. reinhardtii has many known and mapped mutants and expressed sequence tags, and there are advanced methods for genetic transformation and selection of genes. Dictyostelium discoideum is used in molecular biology and genetics, and is studied as an example of cell communication, differentiation, and programmed cell death.

Laboratory mice, widely used in medical research

Among invertebrates, the fruit fly Drosophila melanogaster is famous as the subject of genetics experiments by Thomas Hunt Morgan and others. They are easily raised in the lab, with rapid generations, high fecundity, few chromosomes, and easily induced observable mutations. The nematode Caenorhabditis elegans is used for understanding the genetic control of development and physiology. It was first proposed as a model for neuronal development by Sydney Brenner in 1963, and has been extensively used in many different contexts since then. C. elegans was the first multicellular organism whose genome was completely sequenced, and as of 2012, the only organism to have its connectome (neuronal "wiring diagram") completed.

Arabidopsis thaliana is currently the most popular model plant. Its small stature and short generation time facilitates rapid genetic studies, and many phenotypic and biochemical mutants have been mapped. A. thaliana was the first plant to have its genome sequenced.

Among vertebrates, guinea pigs (Cavia porcellus) were used by Robert Koch and other early bacteriologists as a host for bacterial infections, becoming a byword for "laboratory animal," but are less commonly used today. The classic model vertebrate is currently the mouse (Mus musculus). Many inbred strains exist, as well as lines selected for particular traits, often of medical interest, e.g. body size, obesity, muscularity, and voluntary wheel-running behavior. The rat (Rattus norvegicus) is particularly useful as a toxicology model, and as a neurological model and source of primary cell cultures, owing to the larger size of organs and suborganellar structures relative to the mouse, while eggs and embryos from Xenopus tropicalis and Xenopus laevis (African clawed frog) are used in developmental biology, cell biology, toxicology, and neuroscience. Likewise, the zebrafish (Danio rerio) has a nearly transparent body during early development, which provides unique visual access to the animal's internal anatomy during this time period. Zebrafish are used to study development, toxicology and toxicopathology, specific gene function and roles of signaling pathways.

Other important model organisms and some of their uses include: T4 phage (viral infection), Tetrahymena thermophila (intracellular processes), maize (transposons), hydras (regeneration and morphogenesis), cats (neurophysiology), chickens (development), dogs (respiratory and cardiovascular systems), Nothobranchius furzeri (aging), and non-human primates such as the rhesus macaque and chimpanzee (hepatitis, HIV, Parkinson's disease, cognition, and vaccines).

Selected model organisms

The organisms below have become model organisms because they facilitate the study of certain characters or because of their genetic accessibility. For example, E. coli was one of the first organisms for which genetic techniques such as transformation or genetic manipulation has been developed.

The genomes of all model species have been sequenced, including their mitochondrial/chloroplast genomes. Model organism databases exist to provide researchers with a portal from which to download sequences (DNA, RNA, or protein) or to access functional information on specific genes, for example the sub-cellular localization of the gene product or its physiological role.


Model Organism Common name Informal classification Usage (examples)
Virus Phi X 174 ΦX174 Virus evolution
Prokaryote Escherichia coli E. coli Bacteria bacterial genetics, metabolism
Eukaryote, unicellular Dictyostelium discoideum
Amoeba immunology, host–pathogen interactions
Saccharomyces cerevisiae Brewer's yeast
Baker's yeast
Yeast cell division, organelles, etc.
Schizosaccharomyces pombe Fission yeast Yeast cell cycle, cytokinesis, chromosome biology, telomeres, DNA metabolism, cytoskeleton organization, industrial applications
Chlamydomonas reinhardtii
Algae hydrogen production
Tetrahymena thermophila, T. pyriformis
Ciliate education, biomedical research
Emiliania huxleyi
Plankton surface sea temperature
Plant Arabidopsis thaliana Thale cress Flowering plant population genetics
Physcomitrella patens Spreading earthmoss Moss molecular farming
Populus trichocarpa Balsam popular Tree drought tolerance, lignin biosynthesis, wood formation, plant biology, morphology, genetics, and ecology
Animal, nonvertebrate Caenorhabditis elegans Nematode, Roundworm Worm differentiation, development
Drosophila melanogaster Fruit fly Insect developmental biology, human brain degenerative disease
Callosobruchus maculatus Cowpea Weevil Insect developmental biology
Animal, vertebrate Danio rerio Zebrafish Fish embryonic development
Fundulus heteroclitus Mummichog Fish effect of hormones on behavior
Nothobranchius furzeri Turquoise killifish Fish aging, disease, evolution
Oryzias latipes Japanese rice fish Fish fish biology, sex determination
Anolis carolinensis Carolina anole Reptile reptile biology, evolution
Mus musculus House mouse Mammal disease model for humans
Gallus gallus Red junglefowl Bird embryological development and organogenesis
Taeniopygia castanotis Australian zebra finch Bird vocal learning, neurobiology
Xenopus laevis
Xenopus tropicalis
African clawed frog
Western clawed frog
Amphibian embryonic development

Limitations

Many animal models serving as test subjects in biomedical research, such as rats and mice, may be selectively sedentary, obese and glucose intolerant. This may confound their use to model human metabolic processes and diseases as these can be affected by dietary energy intake and exercise. Similarly, there are differences between the immune systems of model organisms and humans that lead to significantly altered responses to stimuli, although the underlying principles of genome function may be the same. The impoverished environments inside standard laboratory cages deny research animals of the mental and physical challenges are necessary for healthy emotional development. Without day-to-day variety, risks and rewards, and complex environments, some have argued that animal models are irrelevant models of human experience.

Mice differ from humans in several immune properties: mice are more resistant to some toxins than humans; have a lower total neutrophil fraction in the blood, a lower neutrophil enzymatic capacity, lower activity of the complement system, and a different set of pentraxins involved in the inflammatory process; and lack genes for important components of the immune system, such as IL-8, IL-37, TLR10, ICAM-3, etc. Laboratory mice reared in specific-pathogen-free (SPF) conditions usually have a rather immature immune system with a deficit of memory T cells. These mice may have limited diversity of the microbiota, which directly affects the immune system and the development of pathological conditions. Moreover, persistent virus infections (for example, herpesviruses) are activated in humans, but not in SPF mice, with septic complications and may change the resistance to bacterial coinfections. “Dirty” mice are possibly better suitable for mimicking human pathologies. In addition, inbred mouse strains are used in the overwhelming majority of studies, while the human population is heterogeneous, pointing to the importance of studies in interstrain hybrid, outbred, and nonlinear mice.

Unintended bias

Some studies suggests that inadequate published data in animal testing may result in irreproducible research, with missing details about how experiments are done omitted from published papers or differences in testing that may introduce bias. Examples of hidden bias include a 2014 study from McGill University in Montreal, Canada which suggests that mice handled by men rather than women showed higher stress levels. Another study in 2016 suggested that gut microbiomes in mice may have an impact upon scientific research.

Alternatives

Ethical concerns, as well as the cost, maintenance and relative inefficiency of animal research has encouraged development of alternative methods for the study of disease. Cell culture, or in vitro studies, provide an alternative that preserves the physiology of the living cell, but does not require the sacrifice of an animal for mechanistic studies. Human, inducible pluripotent stem cells can also elucidate new mechanisms for understanding cancer and cell regeneration. Imaging studies (such as MRI or PET scans) enable non-invasive study of human subjects. Recent advances in genetics and genomics can identify disease-associated genes, which can be targeted for therapies.

Many biomedical researchers argue that there is no substitute for a living organism when studying complex interactions in disease pathology or treatments.

Ethics

Debate about the ethical use of animals in research dates at least as far back as 1822 when the British Parliament under pressure from British and Indian intellectuals enacted the first law for animal protection preventing cruelty to cattle. This was followed by the Cruelty to Animals Act of 1835 and 1849, which criminalized ill-treating, over-driving, and torturing animals. In 1876, under pressure from the National Anti-Vivisection Society, the Cruelty to Animals Act was amended to include regulations governing the use of animals in research. This new act stipulated that 1) experiments must be proven absolutely necessary for instruction, or to save or prolong human life; 2) animals must be properly anesthetized; and 3) animals must be killed as soon as the experiment is over. Today, these three principles are central to the laws and guidelines governing the use of animals and research. In the U.S., the Animal Welfare Act of 1970 (see also Laboratory Animal Welfare Act) set standards for animal use and care in research. This law is enforced by APHIS's Animal Care program.

In academic settings in which NIH funding is used for animal research, institutions are governed by the NIH Office of Laboratory Animal Welfare (OLAW). At each site, OLAW guidelines and standards are upheld by a local review board called the Institutional Animal Care and Use Committee (IACUC). All laboratory experiments involving living animals are reviewed and approved by this committee. In addition to proving the potential for benefit to human health, minimization of pain and distress, and timely and humane euthanasia, experimenters must justify their protocols based on the principles of Replacement, Reduction and Refinement.

"Replacement" refers to efforts to engage alternatives to animal use. This includes the use of computer models, non-living tissues and cells, and replacement of “higher-order” animals (primates and mammals) with “lower” order animals (e.g. cold-blooded animals, invertebrates) wherever possible.

"Reduction" refers to efforts to minimize number of animals used during the course of an experiment, as well as prevention of unnecessary replication of previous experiments. To satisfy this requirement, mathematical calculations of statistical power are employed to determine the minimum number of animals that can be used to get a statistically significant experimental result.

"Refinement" refers to efforts to make experimental design as painless and efficient as possible in order to minimize the suffering of each animal subject.

Montreal Protocol

From Wikipedia, the free encyclopedia
 
Montreal Protocol
Signed16 September 1987
LocationMontreal
Effective1 January 1989 if 11 states have ratified by then.
ConditionRatification by 20 states
Signatories46
Ratifiers197 (all United Nations members, as well as Niue, the Cook Islands, the Holy See and the European Union)
DepositarySecretary-General of the United Nations
LanguagesArabic, Chinese, English, French, Russian, and Spanish.
The largest Antarctic ozone hole recorded as of September 2006
 
The Montreal Protocol is an international treaty designed to protect the ozone layer by phasing out the production of numerous substances that are responsible for ozone depletion. It was agreed on 16 September 1987, and entered into force on 1 January 1989. Since then, it has undergone nine revisions, in 1990 (London), 1991 (Nairobi), 1992 (Copenhagen), 1993 (Bangkok), 1995 (Vienna), 1997 (Montreal), 1998 (Australia), 1999 (Beijing) and 2016 (Kigali) As a result of the international agreement, the ozone hole in Antarctica is slowly recovering. Climate projections indicate that the ozone layer will return to 1980 levels between 2050 and 2070. Due to its widespread adoption and implementation, it has been hailed as an example of successful international co-operation. Former UN Secretary-General Kofi Annan stated that "perhaps the single most successful international agreement to date has been the Montreal Protocol". In comparison, effective burden-sharing and solution proposals mitigating regional conflicts of interest have been among the success factors for the ozone depletion challenge, where global regulation based on the Kyoto Protocol has failed to do so. In this case of the ozone depletion challenge, there was global regulation already being installed before a scientific consensus was established. Also, overall public opinion was convinced of possible imminent risks.

The two ozone treaties have been ratified by 197 parties (196 states and the European Union), making them the first universally ratified treaties in United Nations history.

These truly universal treaties have also been remarkable in the expedience of the policy-making process at the global scale, where only 14 years lapsed between a basic scientific research discovery (1973) and the international agreement signed (1985 and 1987).

Terms and purposes

The treaty is structured around several groups of halogenated hydrocarbons that deplete stratospheric ozone. All of the ozone depleting substances controlled by the Montreal Protocol contain either chlorine or bromine (substances containing only fluorine do not harm the ozone layer). Some ozone-depleting substances (ODSs) are not yet controlled by the Montreal Protocol, including nitrous oxide (N2O) For a table of ozone-depleting substances controlled by the Montreal Protocol see:

For each group of ODSs, the treaty provides a timetable on which the production of those substances must be shot out and eventually eliminated. This included a 10-year phase-in for developing countries identified in Article 5 of the treaty.

Chlorofluorocarbons (CFCs) Phase-out Management Plan

The stated purpose of the treaty is that the signatory states

Recognizing that worldwide emissions of certain substances can significantly deplete and otherwise modify the ozone layer in a manner that is likely to result in adverse effects on human health and the environment. Determined to protect the ozone layer by taking precautionary measures to control equitably total global emissions of substances that deplete it with the ultimate objective of their elimination on the basis of developments in scientific knowledge

Acknowledging that special provision is required to meet the needs of developing countries

shall accept a series of stepped limits on CFC use and production, including:

  • from 1991 to 1992 its levels of consumption and production of the controlled substances in Group I of Annex A do not exceed 150 percent of its calculated levels of production and consumption of those substances in 1986;
  • from 1994 its calculated level of consumption and production of the controlled substances in Group I of Annex A does not exceed, annually, twenty-five percent of its calculated level of consumption and production in 1986.
  • from 1996 its calculated level of consumption and production of the controlled substances in Group I of Annex A does not exceed zero.

There was a faster phase-out of halon-1211, -2402, -1301, There was a slower phase-out (to zero by 2010) of other substances (halon 1211, 1301, 2402; CFCs 13, 111, 112, etc.) and some chemicals were given individual attention (Carbon tetrachloride; 1,1,1-trichloroethane). The phasing-out of the less damaging HCFCs only began in 1996 and will go on until a complete phasing-out is achieved by 2030.

There were a few exceptions for "essential uses" where no acceptable substitutes were initially found (for example, in the past metered dose inhalers commonly used to treat asthma and chronic obstructive pulmonary disease were exempt) or Halon fire suppression systems used in submarines and aircraft (but not in general industry).

The substances in Group I of Annex A are:

The provisions of the Protocol include the requirement that the Parties to the Protocol base their future decisions on the current scientific, environmental, technical, and economic information that is assessed through panels drawn from the worldwide expert communities. To provide that input to the decision-making process, advances in understanding on these topics were assessed in 1989, 1991, 1994, 1998 and 2002 in a series of reports entitled Scientific assessment of ozone depletion, by the Scientific Assessment Panel (SAP).

In 1990 a Technology and Economic Assessment Panel was also established as the technology and economics advisory body to the Montreal Protocol Parties. The Technology and Economic Assessment Panel (TEAP) provides, at the request of Parties, technical information related to the alternative technologies that have been investigated and employed to make it possible to virtually eliminate use of Ozone Depleting Substances (such as CFCs and Halons), that harm the ozone layer. The TEAP is also tasked by the Parties every year to assess and evaluate various technical issues including evaluating nominations for essential use exemptions for CFCs and halons, and nominations for critical use exemptions for methyl bromide. TEAP's annual reports are a basis for the Parties' informed decision-making.

Numerous reports have been published by various inter-governmental, governmental and non-governmental organizations to catalogue and assess alternatives to the ozone depleting substances, since the substances have been used in various technical sectors, like in refrigeration, air conditioning, flexible and rigid foam, fire protection, aerospace, electronics, agriculture, and laboratory measurements.

Hydrochlorofluorocarbons (HCFCs) Phase-out Management Plan (HPMP)

Under the Montreal Protocol on Substances that Deplete the Ozone Layer, especially Executive Committee (ExCom) 53/37 and ExCom 54/39, Parties to this Protocol agreed to set year 2013 as the time to freeze the consumption and production of HCFCs for developing countries. For developed countries, reduction of HCFC consumption and production began in 2004 and 2010, respectively, with 100% reduction set for 2020. Developing countries agreed to start reducing its consumption and production of HCFCs by 2015, with 100% reduction set for 2030.

Hydrochlorofluorocarbons, commonly known as HCFCs, are a group of man-made compounds containing hydrogen, chlorine, fluorine and carbon. They are not found anywhere in nature. HCFC production began to take off after countries agreed to phase out the use of CFCs in the 1980s, which were found to be destroying the ozone layer. Like CFCs, HCFCs are used for refrigeration, aerosol propellants, foam manufacture and air conditioning. Unlike the CFCs, however, most HCFCs are broken down in the lowest part of the atmosphere and pose a much smaller risk to the ozone layer. Nevertheless, HCFCs are very potent greenhouse gases, despite their very low atmospheric concentrations, measured in parts per trillion (million million).

The HCFCs are transitional CFCs replacements, used as refrigerants, solvents, blowing agents for plastic foam manufacture, and fire extinguishers. In terms of ozone depletion potential (ODP), in comparison to CFCs that have ODP 0.6 – 1.0, these HCFCs have lower ODPs (0.01 – 0.5). In terms of global warming potential (GWP), in comparison to CFCs that have GWP 4,680 – 10,720, HCFCs have lower GWPs (76 – 2,270).

Hydrofluorocarbons (HFCs)

On 1 January 2019 the Kigali Amendment to the Montreal Protocol came into force. Under the Kigali Amendment countries promised to reduce the use of hydrofluorocarbons (HFCs) by more than 80% over the next 30 years. By 27 December 2018, 65 countries had ratified the Amendment.

Produced mostly in developed countries, hydrofluorocarbons (HFCs) replaced CFCs and HCFCs. HFCs pose no harm to the ozone layer because, unlike CFCs and HCFCs, they do not contain chlorine. They are, however, greenhouse gases, with a high global warming potential (GWP), comparable to that of CFCs and HCFCs. In 2009, a study calculated that a fast phasedown of high-GWP HFCs could potentially prevent the equivalent of up to 8.8 Gt CO2-eq per year in emissions by 2050. A proposed phasedown of HFCs was hence projected to avoid up to 0.5C of warming by 2100 under the high-HFC growth scenario, and up to 0.35C under the low-HFC growth scenario. Recognizing the opportunity presented for fast and effective phasing down of HFCs through the Montreal Protocol, starting in 2009 the Federated States of Micronesia proposed an amendment to phase down high-GWP HFCs, with the U.S., Canada, and Mexico following with a similar proposal in 2010.

After seven years of negotiations, in October 2016 at the 28th Meeting of the Parties to the Montreal Protocol in Kigali, the Parties to the Montreal Protocol adopted the Kigali Amendment whereby the Parties agreed to phase down HFCs under the Montreal Protocol. The amendment to the legally-binding Montreal Protocol will ensure that industrialised countries bring down their HFC production and consumption by at least 85 per cent compared to their annual average values in the period 2011–2013. A group of developing countries including China, Brazil and South Africa are mandated to reduce their HFC use by 85 per cent of their average value in 2020-22 by the year 2045. India and some other developing countries – Iran, Iraq, Pakistan, and some oil economies like Saudi Arabia and Kuwait – will cut down their HFCs by 85 per cent of their values in 2024-26 by the year 2047.

On 17 November 2017, ahead of the 29th Meeting of the Parties of the Montreal Protocol, Sweden became the 20th Party to ratify the Kigali Amendment, pushing the Amendment over its ratification threshold ensuring that the Amendment would enter into force 1 January 2019.

History

In the 1970s, the chemists Frank Sherwood Rowland and Mario Molina, who were then at the University of California, Irvine, began studying the impacts of CFCs in the Earth's atmosphere. They discovered that CFC molecules were stable enough to remain in the atmosphere until they got up into the middle of the stratosphere where they would finally (after an average of 50–100 years for two common CFCs) be broken down by ultraviolet radiation releasing a chlorine atom. Rowland and Molina then proposed that these chlorine atoms might be expected to cause the breakdown of large amounts of ozone (O3) in the stratosphere. Their argument was based upon an analogy to contemporary work by Paul J. Crutzen and Harold Johnston, which had shown that nitric oxide (NO) could catalyze the destruction of ozone. (Several other scientists, including Ralph Cicerone, Richard Stolarski, Michael McElroy, and Steven Wofsy had independently proposed that chlorine could catalyze ozone loss, but none had realized that CFCs were a potentially large source of chlorine.) Crutzen, Molina and Rowland were awarded the 1995 Nobel Prize for Chemistry for their work on this problem.

The environmental consequence of this discovery was that, since stratospheric ozone absorbs most of the ultraviolet-B (UV-B) radiation reaching the surface of the planet, depletion of the ozone layer by CFCs would lead to an increase in UV-B radiation at the surface, resulting in an increase in skin cancer and other impacts such as damage to crops and to marine phytoplankton.

But the Rowland-Molina hypothesis was strongly disputed by representatives of the aerosol and halocarbon industries. The chair of the board of DuPont was quoted as saying that ozone depletion theory is "a science fiction tale...a load of rubbish...utter nonsense". Robert Abplanalp, the president of Precision Valve Corporation (and inventor of the first practical aerosol spray can valve), wrote to the Chancellor of UC Irvine to complain about Rowland's public statements (Roan, p. 56.)

After publishing their pivotal paper in June 1974, Rowland and Molina testified at a hearing before the U.S. House of Representatives in December 1974. As a result, significant funding was made available to study various aspects of the problem and to confirm the initial findings. In 1976, the U.S. National Academy of Sciences (NAS) released a report that confirmed the scientific credibility of the ozone depletion hypothesis. NAS continued to publish assessments of related science for the next decade.

Then, in 1985, British Antarctic Survey scientists Joe Farman, Brian Gardiner and Jon Shanklin published results of abnormally low ozone concentrations above Halley Bay near the South Pole. They speculated that this was connected to increased levels of CFCs in the atmosphere. It took several other attempts to establish the Antarctic losses as real and significant, especially after NASA had retrieved matching data from its satellite recordings. The impact of these studies, the metaphor 'ozone hole', and the colourful visual representation in a time lapse animation proved shocking enough for negotiators in Montreal, Canada to take the issue seriously.

Parties subscribed to the Montreal Protocol by region, 1987-2013

Also in 1985, 20 nations, including most of the major CFC producers, signed the Vienna Convention, which established a framework for negotiating international regulations on ozone-depleting substances. After the discovery of the ozone hole by SAGE 2 it only took 18 months to reach a binding agreement in Montreal, Canada.

But the CFC industry did not give up that easily. As late as 1986, the Alliance for Responsible CFC Policy (an association representing the CFC industry founded by DuPont) was still arguing that the science was too uncertain to justify any action. In 1987, DuPont testified before the US Congress that "We believe there is no imminent crisis that demands unilateral regulation." And even in March 1988, Du Pont Chair Richard E. Heckert would write in a letter to the United States Senate, "we will not produce a product unless it can be made, used, handled and disposed of safely and consistent with appropriate safety, health and environmental quality criteria. At the moment, scientific evidence does not point to the need for dramatic CFC emission reductions. There is no available measure of the contribution of CFCs to any observed ozone change..."

Multilateral Fund

The main objective of the Multilateral Fund for the Implementation of the Montreal Protocol is to assist developing country parties to the Montreal Protocol whose annual per capita consumption and production of ozone depleting substances (ODS) is less than 0.3 kg to comply with the control measures of the Protocol. Currently, 147 of the 196 Parties to the Montreal Protocol meet these criteria (they are referred to as Article 5 countries).

It embodies the principle agreed at the United Nations Conference on Environment and Development in 1992 that countries have a common but differentiated responsibility to protect and manage the global commons.

The Fund is managed by an executive committee with an equal representation of seven industrialized and seven Article 5 countries, which are elected annually by a Meeting of the Parties. The Committee reports annually to the Meeting of the Parties on its operations. The work of the Multilateral Fund on the ground in developing countries is carried out by four Implementing Agencies, which have contractual agreements with the executive committee:

Up to 20 percent of the contributions of contributing parties can also be delivered through their bilateral agencies in the form of eligible projects and activities.

The fund is replenished on a three-year basis by the donors. Pledges amount to US$3.1 billion over the period 1991 to 2005. Funds are used, for example, to finance the conversion of existing manufacturing processes, train personnel, pay royalties and patent rights on new technologies, and establish national ozone offices.

Parties

As of 23 June 2015, all countries in the United Nations, the Cook Islands, Holy See, Niue as well as the European Union have ratified the original Montreal Protocol (see external link below), with South Sudan being the last country to ratify the agreement, bringing the total to 197. These countries have also ratified the London, Copenhagen, Montreal, and Beijing amendments.

Effect

Ozone-depleting gas trends

Since the Montreal Protocol came into effect, the atmospheric concentrations of the most important chlorofluorocarbons and related chlorinated hydrocarbons have either leveled off or decreased. Halon concentrations have continued to increase, as the halons presently stored in fire extinguishers are released, but their rate of increase has slowed and their abundances are expected to begin to decline by about 2020. Also, the concentration of the HCFCs increased drastically at least partly because of many uses (e.g. used as solvents or refrigerating agents) CFCs were substituted with HCFCs. While there have been reports of attempts by individuals to circumvent the ban, e.g. by smuggling CFCs from undeveloped to developed nations, the overall level of compliance has been high. Statistical analysis from 2010 show a clear positive signal from the Montreal Protocol to the stratospheric ozone. In consequence, the Montreal Protocol has often been called the most successful international environmental agreement to date. In a 2001 report, NASA found the ozone thinning over Antarctica had remained the same thickness for the previous three years, however in 2003 the ozone hole grew to its second largest size. The most recent (2006) scientific evaluation of the effects of the Montreal Protocol states, "The Montreal Protocol is working: There is clear evidence of a decrease in the atmospheric burden of ozone-depleting substances and some early signs of stratospheric ozone recovery." However, a more recent study seems to point to a relative increase in CFCs due to an unknown source.

Reported in 1997, significant production of CFCs occurred in Russia for sale on the black market to the EU throughout the 90s. Related US production and consumption was enabled by fraudulent reporting due to poor enforcement mechanisms. Similar illegal markets for CFCs were detected in Taiwan, Korea, and Hong Kong.

The Montreal Protocol is also expected to have effects on human health. A 2015 report by the U. S. Environmental Protection Agency estimates that the protection of the ozone layer under the treaty will prevent over 280 million cases of skin cancer, 1.5 million skin cancer deaths, and 45 million cataracts in the United States.

However, the hydrochlorofluorocarbons, or HCFCs, and hydrofluorocarbons, or HFCs, are now thought to contribute to anthropogenic global warming. On a molecule-for-molecule basis, these compounds are up to 10,000 times more potent greenhouse gases than carbon dioxide. The Montreal Protocol currently calls for a complete phase-out of HCFCs by 2030, but does not place any restriction on HFCs. Since the CFCs themselves are equally powerful greenhouse gases, the mere substitution of HFCs for CFCs does not significantly increase the rate of anthropogenic climate change, but over time a steady increase in their use could increase the danger that human activity will change the climate.

Policy experts have advocated for increased efforts to link ozone protection efforts to climate protection efforts. Policy decisions in one arena affect the costs and effectiveness of environmental improvements in the other.

Regional detections of non-compliance

In 2018, scientists monitoring the atmosphere following the 2010 phaseout date have reported evidence of continuing industrial production of CFC-11, likely in eastern Asia, with detrimental global effects on the ozone layer. A monitoring study detected fresh atmospheric releases of carbon tetrachloride from China's Shandong province, beginning sometime after 2012, and accounting for a large part of emissions exceeding global estimates under the Montreal Protocol.

25th anniversary celebrations

The year 2012 marked the 25th anniversary of the signing of the Montreal Protocol. Accordingly, the Montreal Protocol community organized a range of celebrations at the national, regional and international levels to publicize its considerable success to date and to consider the work ahead for the future. Among its accomplishments are: The Montreal Protocol was the first international treaty to address a global environmental regulatory challenge; the first to embrace the "precautionary principle" in its design for science-based policymaking; the first treaty where independent experts on atmospheric science, environmental impacts, chemical technology, and economics, reported directly to Parties, without edit or censorship, functioning under norms of professionalism, peer review, and respect; the first to provide for national differences in responsibility and financial capacity to respond by establishing a multilateral fund for technology transfer; the first MEA with stringent reporting, trade, and binding chemical phase-out obligations for both developed and developing countries; and, the first treaty with a financial mechanism managed democratically by an executive board with equal representation by developed and developing countries.

Within 25 years of signing, parties to the MP celebrate significant milestones. Significantly, the world has phased-out 98% of the Ozone-Depleting Substances (ODS) contained in nearly 100 hazardous chemicals worldwide; every country is in compliance with stringent obligations; and, the MP has achieved the status of the first global regime with universal ratification; even the newest member state, South Sudan, ratified in 2013. UNEP received accolades for achieving global consensus that "demonstrates the world’s commitment to ozone protection, and more broadly, to global environmental protection".

Political psychology

From Wikipedia, the free encyclopedia ...